LIPUS effectively alleviates neuroinflammation after SCI and promotes neurological function recovery by regulating microglia-mediated neuroinflammation, whose mechanism is associated with the modulation of NOD-like receptor, IL-17 signaling pathways and the downregulation of hub genes such as CXCR2. This study provides a scientific basis for the clinical application of LIPUS in SCI treatment and a theoretical foundation for exploring multi-modal therapeutic strategies combining LIPUS with other therapies.
Li et al. (Sat,) studied this question.